Firazyr, INN-Icatibant acetate

First Page		Document Content
Date: 2013-07-21 05:09:46 Complement deficiency Peptides Peptide hormones Icatibant Hereditary angioedema Bradykinin Jerini Aspirin Morphine Chemistry Pharmacology Medicine		Firazyr, INN-Icatibant acetate Add to Reading List Source URL: www.ema.europa.eu Download Document from Source Website File Size: 783,50 KB Share Document on Facebook

	[Product Monograph Template - Schedule D] DocID: 1qWQL - View Document
	News Releases Global Home \| CSL Behring US \| CSL Plasma \| All CSL Behring Web Sites DocID: 1qHpD - View Document
	Microsoft Word - CINRYZE.Product Monographdoc DocID: 1qE2h - View Document
	Microsoft Word - FIRAZYR.Product Monographdoc DocID: 1qA9x - View Document
	Fact Sheet CSL BehringCSL Sales $5.5 Billion CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop DocID: 1pVHk - View Document